TABLE 1.
Summary of protocol differences for laboratories participating in the multilaboratory pneumococcal OPA studya
| Protocol variable | Protocol for indicated laboratoryb |
|||||
|---|---|---|---|---|---|---|
| I | II | III | IV | V | VI | |
| Multiplex OPA (MOPA4) (M) or singleplex (S) | S | M | S | S | M | M |
| CDC, mixture (M), or other (O) target strains | M | O | M | CDC | O | O |
| Cultured (C) or frozen (F) target bacteria in assay | F | C | C | F | C | C |
| CDC HL60 differentiation protocol | Yes | Yes | Yes | Yes | Yes | Yes |
| HL60 passage number monitored | Yes | Yes | Yes | Yes | Yes | Yes |
| Baby rabbit (BR) or normal rabbit (NR) serum | BR | NR | BR | BR | BR | BR |
| UAB, CDC, or in-house (I) assay utilized | I | UAB | I | CDC | UAB | UAB |
| Assay protocol reference(s) | 9 | 3 | 11, 19 | 19 | 3 | 3 |
a
The sequence of laboratories does not correspond to their alphabetic identifications in the text, tables, and figures. UAB, University of Alabama at Birmingham.
b
I, GlaxoSmithKline Biologicals, Belgium; II, Radboud University Nijmegen Medical Centre, Netherlands; III, Pfizer Vaccine Research, Pearl River, NY; IV, National Institute for Health and Welfare, Finland; V, Institute of Child Health, University College London, England; VI, Bacterial Respiratory Pathogen Reference Laboratory, University of Alabama.